BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 35171373)

  • 1. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
    Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
    Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects.
    Maniscalco GT; Ferrara AL; Liotti A; Manzo V; Di Battista ME; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Alfieri G; Di Iorio W; Della Rocca G; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Jun; 62():103800. PubMed ID: 35462168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
    Capuano R; Altieri M; Conte M; Bisecco A; d'Ambrosio A; Donnarumma G; Grimaldi E; Coppola N; Medici N; Galdiero M; Tedeschi G; Gallo A
    J Neurol; 2022 Dec; 269(12):6185-6192. PubMed ID: 35879563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
    Gallo A; Capuano R; Donnarumma G; Bisecco A; Grimaldi E; Conte M; d'Ambrosio A; Coppola N; Galdiero M; Tedeschi G
    Neurol Sci; 2021 Sep; 42(9):3523-3526. PubMed ID: 34128150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
    Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
    Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
    Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
    Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
    Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
    Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose.
    Ruggieri S; Aiello A; Tortorella C; Navarra A; Vanini V; Meschi S; Lapa D; Haggiag S; Prosperini L; Cuzzi G; Salmi A; Quartuccio ME; Altera AMG; Garbuglia AR; Ascoli Bartoli T; Galgani S; Notari S; Agrati C; Puro V; Nicastri E; Gasperini C; Goletti D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.
    Benucci M; Damiani A; Gobbi FL; Lari B; Grossi V; Infantino M; Manfredi M
    Immunol Res; 2022 Aug; 70(4):493-500. PubMed ID: 35543863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
    J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.